Balaxi Pharmaceuticals Ltd Share Price – NSE

Trading, Small Cap

Accordingly, one equity share of the company, having face value of Rs 10 each, would be sub-divided into five equity shares, having face value of Rs 2 each, subject to necessary approvals.

“The record date for sub-division/split of equity shares shall be decided by the board and will be intimated to the exchange,” Balaxi Pharma said in a statement.

Balaxi Pharmaceuticals is part of the Balaxi group, which is an IPR based pharmaceuticals player supplying to Angola and Latin America market under the brand ‘Balaxi’. The group is also involved in branding and selling to FMCG products and ancillary products.

The company had reported 65.13% rise in consolidated net profit to Rs 13.59 crore despite a 29.79% increase in sales to Rs 60.79 crore in Q3 FY24 over Q3 FY23.

Powered by Capital Market - Live News

Balaxi Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 February 2024.

Powered by Capital Market - Live News

Net profit of Balaxi Pharmaceuticals rose 65.13% to Rs 13.59 crore in the quarter ended December 2023 as against Rs 8.23 crore during the previous quarter ended December 2022. Sales declined 29.79% to Rs 60.79 crore in the quarter ended December 2023 as against Rs 86.58 crore during the previous quarter ended December 2022.

Powered by Capital Market - Live News

Net profit of Balaxi Pharmaceuticals declined 6.84% to Rs 14.43 crore in the quarter ended September 2023 as against Rs 15.49 crore during the previous quarter ended September 2022. Sales declined 36.65% to Rs 54.72 crore in the quarter ended September 2023 as against Rs 86.38 crore during the previous quarter ended September 2022.

Powered by Capital Market - Live News